Chai Discovery Secures $130 Million Series B Funding to Advance AI-Driven Drug Development

Chai Discovery, a San Francisco-based biotech startup, has successfully raised $130 million in a Series B funding round, elevating its valuation to $1.3 billion. This funding round, announced on December 15, 2025, was co-led by Oak HC/FT and General Catalyst, with participation from existing investors such as OpenAI, Thrive Capital, and Menlo Ventures, as well as newcomers including Emerson Collective and Glade Brook. This latest investment brings Chai Discovery's total funding to over $225 million, following a $70 million Series A round completed in August 2025.

TechCrunch

Chai Discovery aims to revolutionize drug development through its advanced computational models, particularly the recently unveiled Chai 2. This model is designed to create novel antibodies targeting difficult-to-drug diseases. CEO Josh Meier emphasized the potential of these models, stating, “Our latest models can design molecules that have properties we’d want from actual drugs, and tackle challenging targets that have been out of reach.” The company’s goal is to transform biology into an engineering discipline, significantly shortening the drug development timeline.

Fierce Biotech

The funding surge for Chai Discovery reflects a broader trend in the biotech industry, where AI-driven companies are attracting substantial investment. In 2025, venture funding for AI-powered health tech companies reached $10.7 billion, marking a 24% increase from the previous year. This trend highlights the growing confidence in AI's potential to expedite drug discovery processes. Chai Discovery is part of a competitive landscape that includes other well-funded startups like Isomorphic Labs, which raised $600 million in March 2025.

New York Observer

Chai Discovery's leadership has expressed optimism regarding the future of AI in biopharmaceuticals. Meier remarked, “We’re standing on the precipice of a new era for the biopharmaceutical industry,” indicating that early adopters of these technologies in the pharmaceutical sector are likely to reap significant rewards.

Fierce Biotech

Despite the enthusiasm surrounding AI in drug development, some industry experts caution against over-reliance on technology. Critics argue that while AI can enhance efficiency, it cannot replace the nuanced understanding of biology that experienced researchers bring to the table. Concerns about the ethical implications of AI in healthcare also persist, particularly regarding data privacy and the potential for biased algorithms.

Fierce Biotech

• “We’re standing on the precipice of a new era for the biopharmaceutical industry,” — Josh Meier, CEO of Chai Discovery

Fierce Biotech

• “We’re in awe of the rate of progress on the models—what looked like five-year problems just months ago are now getting solved in weeks,” — Josh Meier, CEO of Chai Discovery

New York Observer

Chai Discovery plans to utilize the new capital to expand its commercialization efforts while accelerating research and product development. As the company continues to innovate in AI-driven drug discovery, it remains to be seen how these advancements will impact the broader pharmaceutical landscape.

New York Observer